Shield Therapeutics (LSE:STX) has successfully secured £1.5 million through the placement of new ordinary shares, driven by strong institutional investor demand, to support the growth of its flagship product, ACCRUFeR®, in the U.S. market. The share issuance, completed at a premium, will strengthen the company’s working capital, expand its shareholder base, and position Shield to accelerate sales with the goal of achieving positive cash flow by the end of 2025.
The company’s outlook is shaped by strong technical performance, reflecting positive market momentum. However, financial challenges—including negative profitability and cash flow constraints—remain significant. Valuation metrics, such as a negative P/E ratio and the absence of a dividend yield, also weigh on the stock’s attractiveness.
About Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency with its innovative therapy, ACCRUFeR®/FeRACCRU® (ferric maltol). In the U.S., the company operates through a collaboration with Viatris and has licensed its product to pharmaceutical partners in Europe, China, and Japan. ACCRUFeR® is the first FDA-approved oral iron therapy for iron deficiency and anemia, addressing a significant unmet medical need.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply